GENE ONLINE|News &
Opinion
Blog

2020-09-10| IPO

Google Backed Telehealth Company, Amwell Outlines Details of its Upcoming IPO

by Ruchi Jhonsa
Share To

Telemedicine or virtual care facilitates access to healthcare to patients, forgoing the need to visit hospitals. As the pandemic’s arrival, telehealth usage rates have skyrocketed with many physicians adopting the technology for taking care of their patients. All of this has been made possible by the advances in telecommunications technology and remote monitoring capabilities developed by technology companies.

By Ruchi Jhonsa, Ph.D.

One of these companies, Amwell, founded in 2006 is known for delivering virtual urgent care, pediatrics, telestroke, population health management, telepsychiatry, and chronic disease management services through its proprietary Amwell Platform. With a vast experience, Amwell supplies telehealth solutions to over 2000 hospitals and 55 plan partners that cover about 80 million people in total.

The company raised $365 million in series B funding in 2018 followed by $194 million in Series C funding this year. However, the company’s stake went higher when Google announced a $100 million investment in Amwell. Google’s monetary and technical support will help build Amwell’s virtual technology and expand its health sector footprint.

Related article: Innovative Diagnostics, AI, Blockchain and Telemedicine Boosts COVID-19 Fight

Backed by the technology giant Google, the company decided to go public on August 24th. The details of which were not disclosed until September 8th when the company outlined the terms of its upcoming IPO. The company offers 35 million shares of its Class A common stock to the public for $14 to $16 a share. The company will be listed on the New York Stock Exchange under the ticker symbol “AMWL.” Amwell will earn gross proceedings of $490 million to $560 million, which it plans to utilize to boost research and development and expand its sales team.

Even though Amwell has set its footprint in the market, it still faces strong competition from Livongo and Teladoc, two companies that recently merged in an $18.5 billion deal. Teladoc, currently has a base of 70 million customers in the US alone alongside access to data from Medicare and Medicaid. This will give Livongo a much better opportunity to help millions of customers in Teladoc’s database facing chronic illness. However, with blessings from Google and its large customer base, Amwell has an advantage over its competitors.

Related article: Google to Acquire Wearable Device Pioneer to Boost Healthcare Plans

Reference:

1. https://www.prnewswire.com/news-releases/amwell-announces-launch-of-initial-
public-offering-301125931.html

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
2024-07-11
Advancing Healthcare Accessibility and Sustainable Development
2024-06-11
R&D
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
LATEST
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I
2024-07-23
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
EVENT
Scroll to Top